COLLEGIUM PHARMACEUTICAL, INC
COLLNasdaq
$36.08
↓ -0.5%Jul 17 close · end-of-day
Price
1Y↑ +13.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.4B
Enterprise Value
$1.0B
P/E
17.7
P/S
1.8
P/B
4.6
EV/EBITDA
5.3
PEG
—
FCF Yield
22.8%
Dividend Yield
—
Revenue (TTM)
$796.3M
Net Income (TTM)
$74.9M
Free Cash Flow (TTM)
$329.8M
Gross Margin
60.7%
Operating Margin
23.7%
Net Margin
9.4%
ROE
24.0%
ROIC
—
Debt / Equity
—
Net Cash
$426.0M
Return 1Y
+11.8%
Company profile
Collegium Pharmaceutical, Inc. develops and commercializes medicines for pain management. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone.
- CEO
- Joseph J. Ciaffoni
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 210
- Headquarters
- Massachusetts
- Website
- collegiumpharma.com
Management & directors
- Dieter DavidEVP & General Counsel
- Dreyer ScottEVP & Chief Commercial Officer
- Karnani VikramPresident and CEO
- Smith Thomas BEVP and Chief Medical Officer
- Tupper ColleenEVP & Chief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
COLL Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$193.5M↑ +8.9%
Diluted EPS$0.40↑ +471.4%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $310.0M | $276.9M | $463.9M | $566.8M | $631.4M | $780.6M |
| Gross profit | $179.8M | $150.6M | $209.5M | $326.2M | $377.3M | $463.3M |
| Operating income | $56.2M | $17.6M | $33.3M | $167.0M | $169.9M | $179.6M |
| Net income | $26.8M | $72.0M | -$25.0M | $48.0M | $69.0M | $63.0M |
| Diluted EPS | $0.76 | $1.86 | -$0.74 | $1.29 | $1.86 | $1.73 |
| Operating cash flow | $93.9M | $103.6M | $124.2M | $274.7M | $205.0M | $329.3M |
| Free cash flow | $88.4M | $101.6M | $122.6M | $274.3M | $203.3M | $327.6M |
| Gross margin | 58.0% | 54.4% | 45.2% | 57.5% | 59.8% | 59.3% |
| Operating margin | 18.1% | 6.4% | 7.2% | 29.5% | 26.9% | 23.0% |
| Net margin | 8.6% | 26.0% | -5.4% | 8.5% | 10.9% | 8.1% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $145.3M | $159.3M | $181.9M | $177.8M | $188.0M | $209.4M | $205.4M | $193.5M |
| Gross profit | $90.8M | $96.8M | $98.3M | $97.3M | $108.4M | $129.2M | $128.4M | $117.2M |
| Operating income | $47.5M | $34.8M | $38.1M | $21.7M | $35.1M | $62.1M | $60.8M | $30.9M |
| Net income | $19.6M | $9.3M | $12.5M | $2.4M | $12.0M | $31.5M | $17.0M | $14.5M |
| Diluted EPS | $0.52 | $0.27 | $0.36 | $0.07 | $0.34 | $0.84 | $0.46 | $0.40 |
| Operating cash flow | $67.4M | -$9.0M | $84.6M | $55.4M | $72.4M | $78.4M | $123.0M | $57.1M |
| Free cash flow | $67.1M | -$9.2M | $84.1M | $54.6M | $72.4M | $78.3M | $122.4M | $56.8M |
| Gross margin | 62.5% | 60.8% | 54.0% | 54.8% | 57.7% | 61.7% | 62.5% | 60.6% |
| Operating margin | 32.7% | 21.9% | 20.9% | 12.2% | 18.7% | 29.7% | 29.6% | 16.0% |
| Net margin | 13.5% | 5.9% | 6.9% | 1.4% | 6.4% | 15.0% | 8.3% | 7.5% |
Company news
Jul 20, 2026
Jul 9, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-08 | SANTINI GINO | Option exercise | 8,700 | $16.49 | $143,463.00 | filing |
| 2026-05-18 | Freund John Gordon | Sale | 20 | $34.05 | $681.00 | filing |
| 2026-05-15 | Freund John Gordon | Option exercise | 8,700 | $16.49 | $143,463.00 | filing |
| 2026-05-15 | Freund John Gordon | Sale | 4,127 | $34.54 | $142,546.58 | filing |
| 2026-05-14 | BOHLIN GAREN G | Award | 8,741 | $0.00 | $0.00 | filing |
| 2026-05-14 | Glancy Donovan Michael | Award | 17,482 | $0.00 | $0.00 | filing |
| 2026-05-14 | SANTINI GINO | Award | 8,741 | $0.00 | $0.00 | filing |
| 2026-05-14 | Balice-Gordon Rita J. | Award | 8,741 | $0.00 | $0.00 | filing |
| 2026-05-14 | Lurker Nancy | Award | 8,741 | $0.00 | $0.00 | filing |
| 2026-05-14 | Paya Carlos V | Award | 8,741 | $0.00 | $0.00 | filing |
| 2026-05-14 | Freund John Gordon | Award | 8,741 | $0.00 | $0.00 | filing |
| 2026-05-13 | Lurker Nancy | Sale | 4,500 | $35.97 | $161,860.95 | filing |
| 2026-05-11 | BOHLIN GAREN G | Sale | 8,700 | $37.18 | $323,491.23 | filing |
| 2026-05-11 | BOHLIN GAREN G | Option exercise | 8,700 | $16.49 | $143,463.00 | filing |
| 2026-03-18 | Dieter David· EVP & General Counsel | Sale | 13,976 | $34.92 | $488,099.22 | filing |
| 2026-03-17 | Dieter David· EVP & General Counsel | Tax withholding | 8,840 | $35.72 | $315,764.80 | filing |
| 2026-03-09 | Dieter David· EVP & General Counsel | Sale | 6,224 | $36.65 | $228,109.60 | filing |
| 2026-03-03 | Dreyer Scott· EVP & Chief Commercial Officer | Sale | 46,417 | $40.36 | $1.9M | filing |
| 2026-03-03 | Dreyer Scott· EVP & Chief Commercial Officer | Sale | 3,559 | $40.99 | $145,879.50 | filing |
| 2026-02-10 | Tupper Colleen· EVP & Chief Financial Officer | Tax withholding | 26,679 | $46.75 | $1.2M | filing |
| 2026-02-10 | Dreyer Scott· EVP & Chief Commercial Officer | Tax withholding | 21,615 | $46.75 | $1.0M | filing |
| 2026-02-10 | Tupper Colleen· EVP & Chief Financial Officer | Tax withholding | 11,861 | $46.75 | $554,501.75 | filing |
| 2026-02-10 | Smith Thomas B· EVP and Chief Medical Officer | Tax withholding | 11,538 | $46.75 | $539,401.50 | filing |
| 2026-02-10 | Karnani Vikram· President and CEO | Tax withholding | 11,296 | $46.75 | $528,088.00 | filing |
| 2026-02-10 | Dreyer Scott· EVP & Chief Commercial Officer | Tax withholding | 9,977 | $46.75 | $466,424.75 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.